SST and neoplasm: Combination of molecular and anatomical imaging (hybrid imaging, SPECT/CT and PET/CT) is currently the most sensitive approach for visualization of somatostatin receptor (SST)-positive tumours, in particular neuroendocrine neoplasms (NEN), utilizing radiolabelled somatostatin analogues [1,2,3].